141 related articles for article (PubMed ID: 9987567)
21. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
Mäenpää JU; Ala-Fossi SL
Drugs Aging; 1997 Oct; 11(4):261-70. PubMed ID: 9342556
[TBL] [Abstract][Full Text] [Related]
22. [Tamoxifen and breast cancer: is everything known already?].
Marchetti P; Porzio G; Trapasso T; Baldi PL; Ficorella C
Tumori; 1998; 84(6):A1-5. PubMed ID: 10080686
[No Abstract] [Full Text] [Related]
23. Searching for the ideal SERM.
Poletti A
Pharmacol Res; 1999 May; 39(5):333. PubMed ID: 10328989
[No Abstract] [Full Text] [Related]
24. Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status.
Ilanchezhian S; Thangaraju M; Sachdanandam P
Cancer Biochem Biophys; 1995 Nov; 15(2):83-90. PubMed ID: 8590439
[TBL] [Abstract][Full Text] [Related]
25. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients.
Boccardo F; Bruzzi P; Rubagotti A; Nicolò GU; Rosso R
Oncology; 1981; 38(5):281-5. PubMed ID: 7266969
[TBL] [Abstract][Full Text] [Related]
26. New stars in the sky of treatment for early breast cancer.
Piccart-Gebhart MJ
N Engl J Med; 2004 Mar; 350(11):1140-2. PubMed ID: 15014188
[No Abstract] [Full Text] [Related]
27. Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors.
Kallak TK; Baumgart J; Göransson E; Nilsson K; Poromaa IS; Stavreus-Evers A
Menopause; 2014 Apr; 21(4):383-90. PubMed ID: 24080848
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
[TBL] [Abstract][Full Text] [Related]
29. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Cufer T; Lobelle JP; Mattiaci MR; Piccart M; Paridaens R
Ann Oncol; 2004 Feb; 15(2):211-7. PubMed ID: 14760111
[TBL] [Abstract][Full Text] [Related]
30. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
31. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
[TBL] [Abstract][Full Text] [Related]
32. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
33. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer.
Milla-Santos A; Milla L; Rallo L; Solano V
Breast Cancer Res Treat; 2001 Jan; 65(2):119-24. PubMed ID: 11261827
[TBL] [Abstract][Full Text] [Related]
34. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.
Voipio SK; Komi J; Kangas L; Halonen K; DeGregorio MW; Erkkola RU
Maturitas; 2002 Nov; 43(3):207-14. PubMed ID: 12443837
[TBL] [Abstract][Full Text] [Related]
35. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
Kennecke HF; Olivotto IA; Speers C; Norris B; Chia SK; Bryce C; Gelmon KA
Ann Oncol; 2007 Jan; 18(1):45-51. PubMed ID: 17030545
[TBL] [Abstract][Full Text] [Related]
36. Endometrial blood flow response to estrogen replacement therapy and tamoxifen in asymptomatic, postmenopausal women: a transvaginal Doppler study.
Achiron R; Lipitz S; Frenkel Y; Mashiach S
Ultrasound Obstet Gynecol; 1995 Jun; 5(6):411-4. PubMed ID: 7552804
[TBL] [Abstract][Full Text] [Related]
37. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
38. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
39. The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer.
Keshavarzi Z; Janghorban R; Alipour S; Tahmasebi S; Jokar A
Support Care Cancer; 2019 Apr; 27(4):1325-1334. PubMed ID: 30729333
[TBL] [Abstract][Full Text] [Related]
40. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
Hutchinson L
Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
